Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 1,474 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $184.55, for a total transaction of $272,026.70. Following the sale, the vice president now owns 20,250 shares in the company, valued at $3,737,137.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NYSE EW opened at $183.93 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.69 and a current ratio of 3.66. The firm has a market capitalization of $38.35 billion, a price-to-earnings ratio of 39.13, a P/E/G ratio of 2.35 and a beta of 0.85. Edwards Lifesciences Corp has a 52-week low of $134.53 and a 52-week high of $197.86.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. During the same period last year, the company posted $1.22 EPS. The business’s revenue was up 11.0% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Corp will post 5.29 earnings per share for the current year.
Several analysts have recently commented on EW shares. Bank of America raised their price objective on shares of Edwards Lifesciences from $190.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Canaccord Genuity reiterated a “buy” rating and issued a $215.00 price target (up from $190.00) on shares of Edwards Lifesciences in a report on Monday, March 18th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group lifted their price target on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $203.00 price target on the stock in a report on Thursday, April 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $186.52.
TRADEMARK VIOLATION WARNING: This news story was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/06/16/insider-selling-edwards-lifesciences-corp-nyseew-vp-sells-1474-shares-of-stock.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: What economic reports are most valuable to investors?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.